Tirzepatide for Treatment of CCCA
Tirzepatide for Treatment of CCCA
Recruiting · NCT07734870 · Registry updated 2026-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tirzepatide for Treatment of CCCA | Insulin Resistance, Nutritional and Metabolic Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, disorder of pilosebaceous unit, glucose metabolism disease, hyperinsulinism, hypotrichosis, metabolic disease, skin disorder | Recruiting | Phase 2 | 2026-09-23 | NCT07734870 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| Johns Hopkins University | 579 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins Outpatient Center | Baltimore | United States | 5 |
| Medical Pavilion at Howard County | Columbia | United States | 1 |